- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- PR positive
- PR negative
- EGFR positive
- ER negative
- KRAS positive
- PD-L1 negative
- p16 positive
- BRAF positive
- EGFR negative
- HLA-A positive
- ALK negative
- BRCA1 positive
- BRCA2 positive
- CD20 positive
- IDH positive
- CD19 positive
- HLA positive
- MET positive
- ALK positive
- p16 negative
- IDH negative
- NRAS positive
- ROS1 positive
- ROS1 negative
- TP53 positive
- HLA negative
- PALB2 positive
- HPV positive
- HR positive
- MSI-H positive
- RB1 negative
- HLA-A negative
- MYC positive
- RB1 positive
- dMMR positive
- BRAF negative
- HPV negative
- PIK3CA positive
- MET negative
- NF1 positive
- MGMT negative
- RET positive
- ATM positive
- FLT3 positive
- KIT positive
- RAS positive
- ANA positive
- ARID1A positive
- BCR-ABL1 positive
- BRCA positive
- HRAS positive
- KRAS negative
- MMR positive
- NTRK positive
- CCND1 positive
- CD22 positive
- CD30 positive
- CFTR positive
- CHEK2 positive
- MGMT positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- RAD51 positive
- BCL2 positive
- BRIP1 positive
- HbSS positive
- PD-1 positive
- PMS2 positive
- PTEN positive
- Philadelphia chromosome positive
- anti-dsDNA positive
- RET negative
- BCL6 positive
- FANCA positive
- MMR negative
- TP53 negative
- p53 positive
- AR positive
- CDK4 positive
- FGFR2 positive
- HBsAg negative
- HBsAg positive
- NRAS negative
- PD-1 negative
- RAS negative
- anti-Sm positive
- ctDNA positive
- BRCA negative
- BRCA1 negative
- BRCA2 negative
- CD123 positive
- CD33 positive
- DLL3 positive
- DMD positive
- FMR1 positive
- HBV DNA negative
- HBV DNA positive
- HPV16 positive
- HR negative
- MSI negative
- MSI positive
- MSI-H negative
- MTAP positive
- NF2 positive
- NPM1 positive
- NTRK negative
- NTRK1 positive
- RF positive
- SMARCA4 positive
- STK11 positive
- TROP2 positive
- dMMR negative
- del(17p) positive
- ABCA4 positive
- AKT1 positive
- APC positive
- APOL1 positive
- ASXL1 positive
- BAP1 positive
- BARD1 positive
- BCR-ABL positive
- CD3 positive
- CDK12 positive
- CDK6 positive
- Complex karyotype positive
- EPCAM positive
- FGFR positive
- FGFR3 positive
- FLT3 negative
- GPC3 positive
- GRN positive
- HbSβ0-thalassemia positive
- KMT2A positive
- Ki-67 positive
- MECP2 positive
- MSS negative
- MSS positive
- NBN positive
- PDGFRA positive
- PTPN11 positive
- RAD51C positive
- RAD54L positive
- RUNX1 positive
- SMN1 positive
- TERT positive
- TROP2 negative
- ZnT8 positive
- t(11;14) positive
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- AChR positive
- ARAF positive
- ATR positive
- C5 positive
- CA-125 positive
- CCND2 positive
- CCND3 positive
- CD19 negative
- CD30 negative
- CD4 count positive
- CD4 positive
- CD5 positive
- CD70 positive
- CD8 positive
- CHEK1 positive
- CLDN18.2 positive
- COL7A1 positive
- CTNNB1 positive
- DMPK positive
- DNMT3A positive
- EBV positive
- Ex19del positive
- FANCD2 positive
- FANCL positive
- HBB positive
- HBcAb negative
- HCV RNA positive
- HbSC positive
- IA-2 positive
- IA-2A positive
- IAA positive
- ICA positive
- IL2RG positive
- JAK2 positive
- L858R positive
- MAP2K1 positive
- MLH1 negative
- MRE11 positive
- MSH2 negative
- MSH6 negative
- MuSK positive
- NF1 negative
- PIK3CA negative
- PMS2 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Alopecia from Prior Anti-Cancer Therapy
- Alopecia from Prior Treatment
- Anemia from Prior Anti-Cancer Therapy
- Anti-Platelet Therapies (Aspirin, Anagrelide)
- Anti-Seizure Medications (up to 2 types)
- Antibody-Based Therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
8836 trials
Trials Without a Placebo
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Graves Disease trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests batoclimab, a medication given as weekly injections under the skin, to see if it can help reduce eye bulging in patients with proptosis. The treatment starts with a higher dose for a few months, followed by a lower dose for a few more months. Batoclimab works by adjusting the immune system to decrease inflammation and swelling around the eyes.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a vaccine to protect older adults from serious E. coli infections. The vaccine trains the immune system to recognize and fight off nine types of harmful E. coli bacteria. In earlier studies, a similar vaccine caused fever and/or diarrhea in some participants and provided limited protection against illness.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug, lanifibranor, to see if it can treat adults with a fatty liver disease called NASH, and who also have liver fibrosis stage 2 or 3.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if a new drug, BHV-3000, is safe and effective in treating migraines in children and adolescents.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if lebrikizumab is effective and safe for adults with chronic sinus and nasal polyps who are already using nasal corticosteroids. The study will take around
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 43 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two treatments for women with moderate to severe acne. One treatment helps balance hormones to reduce skin oiliness, while the other kills bacteria and reduces inflammation. The goal is to see which treatment is more effective and potentially reduce the need for long-term antibiotic use.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved
Get notified when new Gastroparesis trials are postedWe'll send you an email whenever new trials are posted
SummaryThis trial seeks to evaluate if CIN-102 can reduce symptoms of diabetic gastroparesis in adults. Participants will compare effects of drug and placebo treatments over 12 weeks.
Columbus, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
1
2
3
…50